Radiolife

Cutting-edge diagnostic platform (RF + AI = Pathogens fingerprints) to revolutionize how diagnostics are currently done globally.

We have a patent, a working prototype, and regulatory approval in Chile, and next, we will develop new diagnostics methods (we are partnering with find to develop the Tuberculosis test), and invest in a breakthrough application through the FDA.

The world needs better diagnostic solutions. There’s no readily available test for a new disease and current solutions are heavily reliant on reagents making them slow, expensive, and susceptible to supply chain bottlenecks, ultimately leading to a bad patient experience.

Cube Scan is a light and portable device for in-vitro analysis that allows the detection of viruses, bacteria, and cancer cells in under-20s, without any reagents, making it the best solution for improving how diagnostics are done today.

Unlike current solutions offered by established companies such as Abbot Laboratories, Johnson and Johnson, Siemens Healthcare, Roche Diagnostic, and Thermo Fischer Scientific, which are heavily reliant on reagents, Radiolife's Cube Scan can quickly and accurately detect the presence of different viruses, bacteria, and cancer cells without the need for reagents, making it a low-cost and effective option for medical facilities, clinics, and businesses.
Although these established companies have a large market share and significant resources, Cube Scan's unique technology and ability to upgrade remotely with new diagnostics through machine learning gives Radiolife a competitive advantage.

Radiolife's Cube Scan technology has several unique features that set it apart from traditional diagnostic solutions and give us a competitive advantage.
First, our technology does not require the use of expensive reagents, which can be a significant cost and supply chain bottleneck for other diagnostic solutions. Instead, Cube Scan uses radio frequency signatures combined with artificial intelligence modeling to detect the presence of different viruses, bacteria, and cancer cells quickly (under 20 seconds), accurately, and at a low cost.
Second, Cube Scan is a light and portable device, making it easier to transport and use in remote or low-resource settings.
Third, we have a patent on our technology, providing a significant barrier to entry for potential competitors.
Overall, these unique features provide Radiolife with a competitive advantage over traditional diagnostic solutions and position us well to disrupt the global diagnostics market.

With Revenue streams that combine the power of recurring revenue with the upfront payment, we will also have revenue streams coming from technology licensing on markets we decide to outsource distribution. Our goal is to sell 58K in year 1 and 150K units in year two with cumulative revenues of $1.4B by the third year.
Our early adopters will be laboratories, hospitals, and large businesses, but we will also have customers from Home use as well as Health Authorities/ Border Control/ Educational organizations / Governmental and Business Facilities.

- Clinical Studies - 50%
- Product Development and Manufacturing - 25%
- IP expansion - 5%
- Marketing and sales - 20%

Radiolife was accepted into the Future of Healthcare 12-month acceleration program provided by The Roux Institute in Portland, Maine which started in 04/2023.

- Radiolife was the winner at the Biotech Unicorn Battle on 02/02/2023 - https://unicorn.events/046
- Radiolife was one of the three recipients of the Healthcare Solutions Grant Program provided by the Institute for Experiential AI - https://bit.ly/4567FBE
- Radiolife secured the 3rd Place at the StartupOS Pitch Event - https://lnkd.in/gBy7uaw3
- Radiolife has been selected among the top 10 fastest-growing startups in Brazil, in the first edition of the Growth Startups Ranking by Fundação Dom Cabral in partnership with AEVO

US11372009B2